| Schedule of anti-dilutive earnings per share |
| Schedule of anti-dilutive earnings per share | |
| | | |
| | |
| | |
THREE MONTHS END | |
| | |
MARCH 31, | |
| | |
2026 | | |
2025 | |
| | |
(Unaudited) | |
| | |
| | |
| |
| Convertible Note (see Note 6) | |
| 22,176,009 | | |
| 319,342 | |
| Series A Preferred (see Note 8) | |
| 5,000,000 | | |
| 5,000,000 | |
| Series B preferred stock (see Note 8) | |
| 1,730,879 | | |
| 1,133,901 | |
| Detachable common stock warrants (see Note 9) | |
| 400,000 | | |
| 400,000 | |
| Total anti-dilutive securities excluded
from diluted weighted average common shares | |
| 29,306,887 | | |
| 6,853,243 | |
|